ClinicalTrials.gg
CompletedNCT01862289PRESHUpdated May 1, 2018

Prevalence of Hyperventilation Syndrome in Difficult Asthma

An interventional study of Diagnostic of chronic hyperventilation syndrome in Difficult Asthma, Severe Persistent Asthma and Hyperventilation Syndrome, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-01.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
151
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Most of asthmatics patients remain uncontrolled despite an inhaled steroids treatment. Chronic hyperventilation syndrome (also called Idiopathic Hyperventilation) occurs in 20 to 40% of asthmatic patients. The purpose of the study is to assess the prevalence of chronic hyperventilation syndrome in a specific population of difficult-to-treat asthmatics patients, those who receive daily high doses of inhaled steroids (≥ 1000 µg of fluticasone with an additional treatment by a long-acting beta 2-agonist (LABA) and who remain uncontrolled (Asthma control test (ACT) \< 18). We plan to realize a systematic assessment of the diagnosis of chronic hyperventilation syndrome with the Nijmegen questionnaire, blood gases at rest, hyperventilation testing and Cardiopulmonary Exercise Testing(CPET). We also will collect demographic information as well as information about asthma history, asthma control and treatment.

Read the detailed description

There is only one visit. During this visit, each patient will complete self-questionnaires like Nijmegen, Hospital Anxiety and Depression Scale(HAD), Short-Form 36(SF36), and Asthma Quality of Life Questionnaire (AQLQ), The participants will have baseline spirometry and fractional exhaled nitric oxide measured at expiratory flow of 50 mL/s (FENO50), blood gases at rest, an hyperventilation challenge and Cardiopulmonary Exercise Testing(CPET) to determine accurately the presence or not of chronic hyperventilation syndrome. The diagnosis is confirmed by two positive tests (Nijmegen, Hyperventilation challenge and blood gases) and the final decision of a medical committee. The first step is to determine the prevalence oh this syndrome in this specific population. The second step is to assess the sensitivity, the specificity, the false positive rate and the false negative rate of the different parameters measured during the tests.

02

Conditions studied

  • Difficult Asthma
  • Severe Persistent Asthma
  • Hyperventilation Syndrome

Keywords

  • difficult asthma
  • hyperventilation syndrome
  • prevalence
03

In context

Asthma

4,841 studies on the registry are indexed under Asthma; 600 are open to participants now.

This study's enrollment of 151 is above the median of 78 across 3,341 interventional studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,592 studies on the registry; 1,033 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • men and women,
  • aged more than 18,
  • non smokers for two years or longer, less than 10 pack/years smoking history,
  • physician-diagnosed asthma,
  • uncontrolled asthma with Asthma control test (ACT) \< 18,
  • historical of reversibility,
  • daily inhaled treatment by at least 2000microg eq beclomethasone,
  • Forced expiratory volume in 1 second (FEV1) > 50% predicted value

Exclusion criteria

Exclusion Criteria:

  • other chronic pulmonary disease,
  • vocal cord dysfunction,
  • pregnancy,
  • Participation in another interventional research trial,
  • unable to provide consent,
  • asthma exacerbation within the last 4 weeks
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    Severe uncontrolled asthma

    Asthmatics patients with uncontrolled symptoms despite a daily treatment by high doses of inhaled steroids and LABA. Diagnostic of chronic hyperventilation syndrome.

    Other: Diagnostic of chronic hyperventilation syndrome

Interventions

  • OtherDiagnostic of chronic hyperventilation syndrome

    Nijmegen questionnaire, Hyperventilation challenge and blood gases

    Also known as: Exploration to sarch a chronic hyperventilation syndrome

06

What researchers measure

Primary outcomes

  1. Diagnostic of the hyperventilation syndrome

    value of Nijmegen questionnaire, of blood gases at rest, of hyperventilation testing and of CPET

    Time frame: Up to 4 hours

Secondary outcomes

  1. Assess the diagnosis value of the nijmegen questionnaire.

    Time frame: Up to 4 hours

  2. Assess the diagnosis value of the blod gases at rest.

    Time frame: up to 4 hours

  3. Assess the diagnosis value of the hyperventilation challenge.

    Time frame: Up to 4 hours

  4. Assess the diagnosis value of the CPET.

    Time frame: Up to 4 hours

07

Study locations

1 site
  • Assistance Publique - Hôpitaux de Paris, Bicêtre Hospital
    Le Kremlin-bicetre, 94 275, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2013 to primary completion in Oct 2016, 41 months.

Of 599 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's 41 months is above that.

Counting every sponsor, half of 649 studies reached it within 23 months; a quarter within 10 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2013
First posted
May 24, 2013
StartActual
Apr 28, 2013
Primary completionActual
Oct 18, 2016
CompletionActual
Oct 18, 2016
Last update
May 1, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01862289
Responsible party
Sponsor
First posted
May 24, 2013
Start date
Apr 28, 2013
Primary completion
Oct 18, 2016
Completion
Oct 18, 2016
Last update
May 1, 2018

Study contacts

Gilles Garcia, MD, PhD
principal investigator · Assistance Publique Hôpitaux de Paris - Bicêtre Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion